MedPath

Metronidazole

Generic Name
Metronidazole
Brand Names
Flagyl, Flagystatin, Likmez, Metrocream, Metrogel, Metrolotion, Nidagel, Noritate, Nuvessa, Pylera, Rosadan, Vandazole
Drug Type
Small Molecule
Chemical Formula
C6H9N3O3
CAS Number
443-48-1
Unique Ingredient Identifier
140QMO216E
Background

Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.

Indication

Metronidazole is indicated for the treatment of confirmed trichomoniasis caused by Trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections. The above anaerobic infections may occur on the skin and skin structures, the abdomen, the heart, reproductive organs, central nervous system, and the respiratory system. Some may also be present in the bloodstream in cases of septicemia. Common infections treated by metronidazole are Bacteroides species infections, Clostridium infections, and Fusobacterium infections, as well as Peptococcus and Peptostreptococcus infections. Topical formulations of metronidazole are indicated for the treatment of inflammatory lesions of rosacea.

It is also used off-label in the treatment of Crohn's disease, as a prophylactic agent after surgery, and in the treatment of Helicobacter pylori infection. It has also been studied in the prevention of preterm births and to treat periodontal disease.

Associated Conditions
Abscess Brain, Abscess, Intra-Abdominal, Anaerobic Bacterial Infection, Bacterial Endocarditis, Bacterial Peritonitis, Bacterial Septicemia, Bacterial Vaginosis (BV), Balantidiasis, Bone and Joint Infections, Central Nervous System Bacterial Infections, Empyema, Endometritis, Endomyometritis, Facial Rosacea, Giardiasis, Gynecological Infection, Helicobacter Pylori Infection, Inflammatory Papule, Inflammatory pustules, Liver Abscess, Amebic, Lower respiratory tract infection bacterial, Lung Abscess, Meningitis, Mixed Vaginal Infections, Mixed Vaginal Infections caused by Trichomonas Vaginalis, candida albicans, Periodontitis, Pneumonia, Postoperative Infections, Pouchitis, Skin and skin structure infections, Tetanus, Trichomonas Vaginitis, Tubo-ovarian abscess, Vaginal Candidiasis, Vaginitis Trichomonal, Vulvovaginitis, Acute Intestinal amebiasis, Asymptomatic Trichomoniasis, Entamoeba histolytica, Hepatic abscess, Intra-abdominal bacterial infections, Post-surgical vaginal cuff infection, Refractory Sinusitis, Symptomatic Trichomoniasis

A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.

Phase 1
Recruiting
Conditions
PHA1A
Interventions
Drug: Zidebactam-Cefepime
First Posted Date
2025-02-04
Last Posted Date
2025-03-05
Lead Sponsor
Wockhardt
Target Recruit Count
30
Registration Number
NCT06806995
Locations
🇺🇸

Advanced Pharma CR, LLC, Miami, Florida, United States

Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis

Phase 2
Recruiting
Conditions
Cutaneous Leishmaniasis
Interventions
First Posted Date
2025-01-29
Last Posted Date
2025-02-14
Lead Sponsor
Hayder Adnan Fawzi
Target Recruit Count
40
Registration Number
NCT06798415
Locations
🇮🇶

Mustansiriyah University, Baghdad, Iraq

Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Phase 2
Recruiting
Conditions
Rectal Cancer, Adenocarcinoma
Interventions
First Posted Date
2025-01-27
Last Posted Date
2025-01-29
Lead Sponsor
AC Camargo Cancer Center
Target Recruit Count
100
Registration Number
NCT06793137
Locations
🇧🇷

A.C Camargo Cancer Center, São Paulo, SP, Brazil

Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study

Not yet recruiting
Conditions
HELICOBACTER PYLORI INFECTIONS
Interventions
First Posted Date
2024-12-12
Last Posted Date
2024-12-19
Lead Sponsor
Xiuli Zuo
Target Recruit Count
30
Registration Number
NCT06731023
Locations
🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

Phase 3
Not yet recruiting
Conditions
Intra-abdominal Infections
Interventions
Drug: Ceftazidime-avibactam
Drug: Saline
First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
786
Registration Number
NCT06633718
Locations
🇨🇳

Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

Phase 2
Not yet recruiting
Conditions
Oral Squamous Cell Carcinoma
Oral Cancer
Head and Neck Cancer
Head and Neck Carcinoma
Interventions
Other: Chlorhexidine
First Posted Date
2024-10-04
Last Posted Date
2025-03-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT06627270
Locations
🇺🇸

Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio, United States

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Phase 2
Recruiting
Conditions
Prostate Cancer (Adenocarcinoma)
Metastatic Prostate Cancer
Interventions
First Posted Date
2024-09-27
Last Posted Date
2025-03-05
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
58
Registration Number
NCT06616597
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Parasitic Infections and Ulcerative Colitis: Combining Anti-parasitic and Immunomodulatory Treatments May Achieve Remission

Not Applicable
Completed
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2024-09-04
Last Posted Date
2024-09-04
Lead Sponsor
Benha University
Target Recruit Count
120
Registration Number
NCT06583863
Locations
🇪🇬

Benha faculty of Medicine, Banhā, El Qalyoubia, Egypt

A Phase II Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Phase 2
Recruiting
Conditions
Rectal Adenocarcinoma
Interventions
First Posted Date
2024-08-26
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT06569368
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males

Phase 4
Conditions
Helicobacter Pylori Infection
Sex
Bismuth Quadruple Therapy
Interventions
First Posted Date
2024-07-19
Last Posted Date
2024-11-07
Lead Sponsor
National Cheng-Kung University Hospital
Target Recruit Count
661
Registration Number
NCT06509139
Locations
🇨🇳

Helicobacter pylori study group, National Cheng Kung University Hospital, Tainan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath